RESEARCHER PROFILE

Daniel Peter Petrylak

← Back to Yale University

D

Yale University

Prostate Cancer Treatment and ResearchBladder and Urothelial Cancer TreatmentsProstate Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersBone health and treatments

Daniel Peter Petrylak works in Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, Prostate Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Bone health and treatments. Recorded institutional associations include Yale Cancer Center, Yale University, Smilow Cancer Hospital.

834Publications
46,397Citations
88H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

    2004 · 3,665 citations
  2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    2016 · 3,665 citations
  3. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    2017 · 3,387 citations
  4. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    2014 · 2,381 citations
  5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    2016 · 2,198 citations
  6. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    2020 · 1,493 citations
  7. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    2021 · 1,229 citations
  8. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    2019 · 1,217 citations
  9. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    1999 · 977 citations
  10. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

    2019 · 642 citations
  11. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

    1996 · 635 citations
  12. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    2021 · 542 citations
  13. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    2020 · 501 citations
  14. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    2019 · 480 citations
  15. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    2016 · 460 citations
  16. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    2021 · 429 citations
  17. Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

    2012 · 416 citations
  18. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

    1995 · 386 citations
  19. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    2007 · 376 citations
  20. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

    2009 · 340 citations
  21. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    2020 · 338 citations
  22. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    2022 · 316 citations
  23. Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

    2007 · 312 citations
  24. Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

    1999 · 311 citations
  25. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

    2017 · 299 citations

← Return to the university profile